Tag: PF1801
-
ImmunoForge to Accelerate Global Partnerships at JPM Healthcare Conference 2026
ImmunoForge to host strategic partnering meetings at JPMorgan Healthcare Conference 2026 ImmunoForge Co., Ltd., a Seoul-based biopharma company focused on advancing immuno-oncology therapies, announced plans to host a series of strategic partnering meetings during the 2026 JPMorgan Healthcare Conference in San Francisco. The company will actively engage with global pharmaceutical leaders to accelerate the U.S.…
-
ImmunoForge Sets Strategic Partnering Meetings at JPM Healthcare Conference 2026 to Out-License Phase 2 Assets PF1801 and PF1804
ImmunoForge Targets Global Partnerships at a Premier Healthcare Conference ImmunoForge Co., Ltd. announces strategic partnering meetings during the 2026 J.P. Morgan Healthcare Conference in San Francisco, with a dedicated focus on the global out-licensing of its Phase 2 assets PF1801 and PF1804. The company, led by co-CEOs Sung-Mi and a leadership team expanding its international…
-
ImmunoForge to Host Partnering Meetings at JPM 2026 Conference
ImmunoForge Sets the Stage for Global Licensing at JPMorgan Healthcare Conference 2026 ImmunoForge Co., Ltd. announces a strategic push at the 2026 JPMorgan Healthcare Conference in San Francisco, focusing on global out-licensing of its Phase 2 assets PF1801 and PF1804. With co-CEOs and a mission to accelerate clinical progress, ImmunoForge plans to engage directly with…